This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Karo Pharma バランスシートの健全性
財務の健全性 基準チェック /16
主要情報
104.8%
負債資本比率
SEK 8.65b
負債
| インタレスト・カバレッジ・レシオ | 0.2x |
| 現金 | SEK 353.10m |
| エクイティ | SEK 8.26b |
| 負債合計 | SEK 10.24b |
| 総資産 | SEK 18.49b |
財務の健全性に関する最新情報
Recent updates
財務状況分析
短期負債: KA6N's short term assets (SEK1.7B) exceed its short term liabilities (SEK626.0M).
長期負債: KA6N's short term assets (SEK1.7B) do not cover its long term liabilities (SEK9.6B).
デット・ツー・エクイティの歴史と分析
負債レベル: KA6N's net debt to equity ratio (100.5%) is considered high.
負債の削減: KA6N's debt to equity ratio has increased from 59.5% to 104.8% over the past 5 years.
債務返済能力: KA6N's debt is not well covered by operating cash flow (5.9%).
インタレストカバレッジ: KA6N's interest payments on its debt are not well covered by EBIT (0.2x coverage).